PT-141 10MG
PT-141, also known as Bremelanotide, is a synthetic peptide that functions as a melanocortin receptor agonist in the central nervous system. This unique mechanism of action makes it a subject of intense research for its potent effects on increasing libido and treating sexual arousal disorders in both men and women.
$60.00
The information provided on this page is intended solely as a general summary. It does not encompass all potential research applications, handling procedures, safety precautions, interactions, or observed effects. These products are supplied strictly for laboratory and research purposes only. They are not intended for human consumption, medical use, veterinary use, or diagnostic purposes. This information must not be considered a substitute for professional expertise, judgment, or regulatory guidance.
Money Back Guarantee
Guaranteed Quality
Fast Shipping
10+ Years Experience
Frequently Bought Together
SEQUENCE/FORMULA
MOLECULAR WEIGHT
PUBCHEM CID
- Investigating its efficacy in treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Studying its potential to treat erectile dysfunction (ED) in men, particularly when unresponsive to PDE5 inhibitors like sildenafil.
- Analyzing its effects on both male and female libido and sexual arousal.
- Researching its use as a rescue treatment for sexual dysfunction induced by other medications.
- Exploring its role in sexual motivation and behavior through its action in the central nervous system.
- Functions as a synthetic analogue of Alpha-Melanocyte-Stimulating Hormone (α-MSH).
- It is a melanocortin receptor agonist, meaning it activates these receptors. Specifically, it has a high affinity for the MC4R (melanocortin 4 receptor) and MC1R subtypes.
- Unlike PDE5 inhibitors that work on the vascular system to increase blood flow, PT-141 acts directly on the central nervous system (the brain) to increase sexual desire and arousal.
- Activation of these melanocortin pathways in the brain is believed to modulate pathways involved in sexual function and motivation.
- Kingsberg, S. A., et al. (2019). The VIOLET studies: two 24-week, phase 3, randomized, double-blind, placebo-controlled trials to evaluate the efficacy and safety of bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder. The Journal of Sexual Medicine, 16(6), 808-819.
- Molinoff, P. B., et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994(1), 96-102.
- Pfaus, J. G., et al. (2004). The pharmacology of sexual arousal. Annual Review of Pharmacology and Toxicology, 44, 585-612.
- Shadiack, A. M., et al. (2007). In vitro and in vivo effects of the melanocortin receptor agonist PT-141 on penile erection. European Journal of Pharmacology, 556(1-3), 136-143.
